
ICON Public Limited Company
ICLR
Updated: 25/09/2026, 09:01:03
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
No summaries found.
- Share price
- $173.90
- Market cap
- $13.32B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Barry Balfe
- Employees
- 40,200
- IPO date
- 15/05/1998
- Beta
- 1.201
- Last dividend
- $0.00
- Day range
- $163.79 – $175.00
- 52-week range
- $66.57 – $203.91
- 1-day performance
- 6.10%
- 1-year performance
- 161.23%
- Current drawdown (1Y)
- -14.72%
- CIK
- 0001060955
- CUSIP
- G4705A100
- ISIN
- IE0005711209
- Created
- 07/12/2025, 04:39:50
- Last update
- 25/09/2026, 09:01:03
Track ICON Public Limited Company with an AI analyst
See which prediction-market events move ICLR, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
ICON Stock Valuation vs Peers: Is ICLR Cheap Enough?
Zacks Investment Research • STOCK • 08/06/2026, 14:52:33
ICLR Earnings Reset: What the Accounting Probe Changed
Zacks Investment Research • STOCK • 05/06/2026, 17:10:23
ICON plc (ICLR) Surges on Analyst Upgrade & Strong Bookings
Market Data • Market Data • 28/05/2026, 21:17:40
ICON Public Limited Company (ICLR) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 28/05/2026, 19:04:07
Icon Q4 Earnings Call Highlights
MarketBeat • STOCK • 28/05/2026, 12:11:58
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
Business Wire • STOCK • 27/05/2026, 18:33:00
ICON plc (NASDAQ:ICLR) Expands US Research Amidst Stock Decline and Upcoming Earnings Report
Market Data • Market Data • 13/05/2026, 19:00:15
Artisan International Value Fund Q1 2026 Portfolio Update
Seeking Alpha • STOCK • 12/05/2026, 08:15:00
The moon is the ‘ULTIMATE HIGH GROUND': ICON Prime president
Fox Business • STOCK • 03/05/2026, 02:00:51
ROYAL CARIBBEAN GROUP CONFIRMS ORDER WITH MEYER TURKU FOR ICON 6 AND 7
PRNewsWire • STOCK • 27/04/2026, 21:00:00
Icon PLC (NASDAQ: ICLR) Q1 2026 Earnings Preview, Analyst Estimates & Institutional Investor Activity
Market Data • Market Data • 31/03/2026, 22:00:09
ICON Public Limited Company's Financial Overview and Challenges
Market Data • Market Data • 17/03/2026, 15:00:05